David Bredt, Chief Scientific Officer at Rapport Therapeutics, Inc. (RAPP), sold 8,500 shares at $9.56 ($81K) on 2025-05-15, disclosed to the SEC on 2025-05-19.
Scheduled sale ($81k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| RAPP | SELL | 2026-01-05 | $395K | — | Filing → |
| RAPP | SELL | 2025-12-16 | $486K | — | Filing → |
| RAPP | SELL | 2025-11-18 | $428K | — | Filing → |